Compare DexCom, Inc. (DXCM) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Okta, Inc. — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while Okta, Inc. trades at $147.32 (market cap $26.13B). The key difference: DexCom, Inc. is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, Okta, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | OKTA | |
|---|---|---|
Market Cap | $33.79B | $26.13B |
Sector | Health | Technology |
52-Week High | $89.53 | $154.62 |
52-Week Low | $54.84 | $62.93 |
Enterprise Value | $33.24B | $23.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
Okta trades at $147.43, down 2.22% today, with a bullish technical signal from moving averages but overbought RSI readings. The company achieved GAAP profitability in 2025 with $28M net income, marking a significant turnaround from prior losses. Recent earnings beats and the acquisition of Permiso Security for AI identity threat defense highlight growth momentum. Operating cash flow surged to $750M in 2025, supporting financial flexibility.
The outlook is positive with strong analyst support (73% buy ratings) and a consensus price target of $129.71, though the current price exceeds this. Risks include high valuation multiples (P/E 108.93) and competitive pressure from Microsoft. Revenue growth to $3.0B in 2026 forecasts sustained expansion, but investor caution is warranted near technical resistance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
